Growing Awareness Driving a Large Demand for the Global Bleeding Disorders Treatment Market; MRFR Releases the Forecast for 2016-2023

Market Overview:

Bleeding disorders result in susceptibility to bleeding due to faulty blood clotting, caused by defect in the blood coagulation. Bleeding disorders treatment includes the drugs used in the treatment and management of such bleeding disorders. The global bleeding disorders treatment market is continually growing owing to the prevalence of bleeding disorders such as hemophilia, platelet disorders, Von Willebrand disease and others.

According to Market Research Future (MRFR), the global Bleeding Disorders Treatment Market is expected to garner a CAGR of over 10.0% over the assessment period (2018-2023). The demographic drivers of the market include the growing incidence of bleeding disorders and the growing population. According to the National Hemophilia Foundation hemophilia affects about 20,000 people in the United States and more than 400,000 people globally. Platelet disorders have an incidence of 1900to 6400 per 10000a year.

Bleeding Disorders Treatment Market – Competitive Landscape

The bleeding disorders treatment market is fragmented and highly competitive due to the presence of plethora of small and large players. A large market is captive owing to purchase by public health sector. Manufacturers rely on close collaboration and partnerships with public players and programmes so as to tap the government purchase of drugs used for bleeding disorders. 

The free market is dominated by large companies having a premium product using advanced technologies such as recombinant DNA, advanced clotting factors and others. Companies are also investing in R&D activities so as to develop new drug molecules. Developments in associated sciences such as protein analysis, recombinant technology is resulting in increased collaboration between players.

Major Players:

·         Shire Plc

·         Pfizer Inc

·         Bayer Pharmaceuticals

·         Biogen Inc

·         BDI Pharma

·         CSL Behring

·         Grifols

·         Sun Pharmaceutical Industries Ltd.

·         Octapharma

·         Ferring Pharmaceuticals

·         Novo Nordisk A/S

Global Bleeding Disorders Treatment Market – Segments

By Type         : Hemophilia A, Hemophilia B, Von Willebrand Disease (vWD), among others.

By Drug Class           : Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrate, among others.

By Treatment           : Medication, Desmopressin (DDAVP), Hormone replacement therapy, Contraceptives, Anti-fibrinolytic/clot-stabilizing drugs, Fibrin sealants, Drugs applied to cuts, among others.

By End-users            : Hospitals, Clinics, Research Institutes, among others.

By Regions               : North America, Europe, Asia Pacific, and the Rest-of-the-World.

Global Bleeding Disorders Treatment Market – Regional Analysis

North America dominates the global bleeding disorders treatment market owing to high cost of treatment, excellent diagnosis rates and reimbursement and compulsory new born screening introduced under the healthcare programme. Government initiatives such as the US National Hemophilia Program (NHP) which is a collaborative effort by Maternal and Child Health Bureau (MCHB) under the auspices of the Health Resources and Services Administration (HRSA), the National Hemophilia Foundation (NHF), and the Centers for Disease Control and Prevention (CDC) is driving a faster market uptake. 

The bleeding disorders treatment market in Europe is dominated by Germany, France, U.K. and the Nordic states. The provisions of tax cuts owing to the approval of rare diseases certificate to many genetic acquired bleeding disorders such as Haemophilia by National Organization for Rare Disorders is driving a large market. The incidence rate of haemophilia in Eu is around 5 per 10 000 people. Establishment of transnational medical bodies such as the European Association for Haemophilia and Allied Disorders (EAHAD), which cares for the provision of care and advancement of rights and welfare of patients suffering from bleeding disorders coupled with greater availability of finance is driving a large market.

The Asia Pacific bleeding disorders treatment market is expected to gain a massive traction owing to large patient pool and the concurrent large potential market. The expanding healthcare infrastructure and diagnostic labs coupled with the availability of affordable test kits and the burgeoning pharma sector is expected to drive a large market value over the study period. 

Industry/ Innovation/ Related News:

April 17, 2019---- Pharmaceutical giant Roche launched in India, Hemlibra (Emicizumab) for the preventive treatment of Haemophilia A. Hemlibra is the first weekly subcutaneous prophylaxis injection which is an improvement in dosing as all current treatments with Haemophilia A with factor VIII inhibitors demand greater frequency of dosing. The drug product is expected to be adopted faster owing to the greater convenience and lower dosing frequency which will improve compliance.